• Success: Retinopathy of Prematurity (Zone I or Posterior II (Stage 3) has not recurred following treatment: Intravitreal Bevacizumab versus Laser Therapy [ Time Frame: 54 weeks adjusted age (6 to 7.5 months of age) ] [ Designated as safety issue: Yes ]
  

• Determination of visual acuity, visual field, refraction, motility examination or any other ocular parameter related to severe ROP [ Time Frame: 80 weeks adjusted age (12 to 13.5 months of age) ] [ Designated as safety issue: Yes ]
  

This phase 2 study will assess the anti-neovascularization activity of intravitreal bevacizumab, as determined by regression of neovascular vessels of retinopathy of prematurity (ROP), in neonates with acute stage 3 ROP in zone I or posterior zone II with plus disease. This study will enroll confirmed cases of vision threatening ROP (between ETROP and CRYO-ROP) which have definite plus disease. This will be done because of the controversy regarding determining plus disease and the increasing concern that many infants are being treated whose ROP would spontaneously regress. Bevacizumab will be administered intravitreally using 0.625 mg (0.025 ml) injections into each eye. There is no intent to give additional doses unless there is a recurrence of vision threatening stage 3 ROP with plus disease since the disease is self limited by completion of vascularization. Clinical response and any evidence of ocular toxicities will be documented both pre- and post-injection by RetCam retinal images and by fluorescein angiography when possible (structural documentation) and at 6 and 12 months of age by electroretinograms and by visual evoked potentials when possible (functional documentation). Any evidence of systemic toxicities will be documented by appropriate clinical and laboratory tests.